A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Anastrozole (Primary) ; Saracatinib (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 19 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 19 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated